Topical clindamycin therapy for acne vulgaris. A cooperative clinical study.
Eleven institutions participated in an eight-week controlled clinical study to evaluate treatment of acne vulgaris with topical clindamycin hydrochloride and clindamycin phosphate. Three hundred fifty-eight patients with comparable baseline pustule, papule, and nodule counts applied 1%, clindamycin hydrochloride, 1% clindamycin phosphate, or a hydroalcoholic vehicle twice daily. Every two weeks, lesions were counted, and patients' evaluations of their acne conditions were scored. By week 8, pustule and papule counts in the groups who were receiving clindamycin were significantly lower than those in the group receiving placebo. Also, more patients who were receiving clindamycin thought their acne improved by week 8 (with significantly higher change-in-acne scores) than did the patients receiving placebo. Patients receiving clindamycin reported 12 episodes of diarrhea; only one episode was considered to be treatment related. These results substantiate the clinical impression that topical clindamycin is effective treatment for acne.
D000433:1-Propanol / Q000008:administration & dosage; D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002648:Child; D002981:Clindamycin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D010919:Placebos; D019946:Propylene Glycol; D011409:Propylene Glycols / Q000008:administration & dosage; D011897:Random Allocation
D009943:Organophosphorus Compounds; D010919:Placebos; D011409:Propylene Glycols; D002981:Clindamycin; D019946:Propylene Glycol; D000433:1-Propanol; C007084:clindamycin phosphate